Back to our stories Elikonos 2 S.C.A. SICAR invests €7M for acquiring a minority stake in Comsys S.A.
02 November, 2021 News

Elikonos 2 S.C.A. SICAR announces its ninth investment of €7m acquiring a minority stake in Comsys S.A. The Company is a leading provider of οmnichannel customer engagement solutions that enable enterprises to deliver a unique customer experience and increase the efficiency of their contact center operations. Comsys S.A. has strategic partnerships with major technology vendors and has completed various complex projects in financial services, telecommunications, and retail sectors in 22 countries. Comsys S.A. was established in 1989 and employs 43 people.

Elikonos 2 S.C.A. SICAR, a private equity fund with total commitments of €85m, is investing in Greek growth and later stage Small & Medium Enterprises (SMEs). Elikonos 2 S.C.A. SICAR received commitments from EquiFund, an investment platform created by the Hellenic Republic in cooperation with the European Investment Fund (EIF), from European Bank for Reconstruction and Development (EBRD), from European Investment Bank (EIB) and Hellenic Development Bank S.A.. Elikonos 2 S.C.A. SICAR is managed by Elikonos Capital Partners S.a.r.l., a company active in the private equity industry since 2021 with total assets under management of €100m.

EquiFund investment platform is an initiative created by cooperation between the Hellenic Republic and EIF. It is financed by the Greek ESIF Fund of Funds TAESYM under the European Union / European Regional Development Fund / Operational Programme EPANEK, the EIF and private investors, with the objective to facilitate access to finance, mainly to SMEs, by developing the Venture Capital/Private Equity (“VC/PE”) in Greece in cooperation with selected Financial Intermediaries.

Share this
Back to our stories

More Stories

  • CFront Assistant on Microsoft Azure Marketplace
    30 March, 2023 News
  • Comsys sponsored the 25th Greek ICT Forum 2023
    24 March, 2023 News
  • Comsys supports the Greece Race for the Cure® 2022
    04 October, 2022 News